Hookipa Pharma Inc (HOOK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hookipa Pharma Inc (HOOK) has a cash flow conversion efficiency ratio of -0.249x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.13 Million) by net assets ($28.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Hookipa Pharma Inc stock valuation for the company's overall valuation and market capitalisation.
Hookipa Pharma Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Hookipa Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hookipa Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hookipa Pharma Inc ranked by their cash flow conversion efficiency. Explore HOOK operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Prasidha Aneka Niaga Tbk
JK:PSDN
|
-0.096x |
|
NTG Clarity Networks Inc.
V:NCI
|
-0.125x |
|
Spring Art Holdings Bhd
KLSE:0216
|
0.013x |
|
Ecomiam SA
PA:ALECO
|
-0.357x |
|
Imexhs Ltd
AU:IME
|
-0.103x |
|
Noble Mineral Exploration Inc
V:NOB
|
-0.069x |
|
Rajshree Sugars & Chemicals Limited
NSE:RAJSREESUG
|
-0.072x |
|
Energisme
PA:ALNRG
|
-1.376x |
Annual Cash Flow Conversion Efficiency for Hookipa Pharma Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Hookipa Pharma Inc from 2017 to 2025. View latest Hookipa Pharma Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $32.52 Million | $-11.50 Million | -0.354x | +76.47% |
| 2024-12-31 | $51.21 Million | $-76.98 Million | -1.503x | -134.79% |
| 2023-12-31 | $89.86 Million | $-57.52 Million | -0.640x | -228.19% |
| 2022-12-31 | $102.52 Million | $-20.00 Million | -0.195x | +73.53% |
| 2021-12-31 | $89.59 Million | $-66.02 Million | -0.737x | -192.43% |
| 2020-12-31 | $156.12 Million | $-39.34 Million | -0.252x | +28.81% |
| 2019-12-31 | $117.90 Million | $-41.73 Million | -0.354x | -4.78% |
| 2018-12-31 | $44.40 Million | $-15.00 Million | -0.338x | -220.95% |
| 2017-12-31 | $-42.66 Million | $-11.91 Million | 0.279x | -- |
About Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancer… Read more